The trial randomized 359 people with acutely exacerbated schizophrenia to receive one of three daily oral doses of LB-102 or placebo. LB-102 is a modified version of amisulpride, a dopamine inhibitor that was developed in the 1980s and marketed by Sanofi as a schizophrenia drug—Solian—outside the U.S.
3 Likes
Amisulpride is a great med. I was on it for couple of months and it improved both my positive and negative symptoms I had to quit taking it becouse my prolactin levels were to high.
3 Likes
i prefer discovering new drug rather than modifying an old one.
1 Like
LB-102 was safe and well-tolerated, with low extrapyramidal symptoms, adverse events linked to increased prolactin, and QT interval prolongation. Only 1 participant on LB-102 reported sedation.
What IS your country ? Because amisulpride IS not on the american market.
In France my country amisulpride IS named solian.
I am from Croatia.
Hello @petar_pan, i have a question ? I want an antipsychotics with not or few weight gain effect. Have you weight gain with amisulpride ?
My antipsychotics abilify IS good but i gained 10 kilograms with it.
See you soon and thanks for your answer.
Sébastien from france
Thank @petar_pan.